NR3C2 and chronic kidney disease: For CKD patients with proteinuria who are at increased risk of cardiovascular events or CKD progression, non-steroidal mineralocorticoid receptor antagonists proven effective in clinical trials are recommended to delay CKD progression and reduce the risk of cardiovascular events, with concurrent monitoring of serum potassium (A); 4.